Direct oral anti-
activated factor X and
antithrombin agents have largely replaced
vitamin K antagonists as the standard of care in treatment of
venous thromboembolism. However, gaps in efficacy and safety persist, notably in
end-stage renal disease, implantable heart valves or assist devices, extracorporeal support of the circulation, and
antiphospholipid syndrome. Inhibition of
coagulation factor XI (FXI) emerges as a promising new therapeutic target.
Antisense oligonucleotides offer potential advantages as a prophylactic or therapeutic modality, with one dose-finding trial in
orthopedic surgery already published. In addition,
monoclonal antibodies blocking activation and/or activity of
activated factor XI are investigated, as are small-molecule inhibitors with rapid offset of action. Further potential targets include upstream components of the contact pathway such as
factor XII,
polyphosphates, or
kallikrein. Finally,
catheter-directed, pharmacomechanical antithrombotic strategies have been developed for high- and intermediate-risk
pulmonary embolism, and large randomized trials aiming to validate their efficacy, safety, and prognostic impact are about to start.